TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05689853: An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors

Sponsor: Akeso · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 87 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05689853 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05689853 Rescue Dossier →